SG10201900323SA - Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells - Google Patents
Method for inducing t cells for cell-based immunotherapy from pluripotent stem cellsInfo
- Publication number
- SG10201900323SA SG10201900323SA SG10201900323SA SG10201900323SA SG10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- cells
- based immunotherapy
- inducing
- pluripotent stem
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 6
- 238000009169 immunotherapy Methods 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 230000001939 inductive effect Effects 0.000 title abstract 4
- 210000001778 pluripotent stem cell Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 101100193633 Danio rerio rag2 gene Proteins 0.000 abstract 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000003209 gene knockout Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
METHODFOR INDUCING T CELLS FOR CELL-BASED IMMUNOTHERAPY FROM PLURIPOTENT STEM CELLS OF DISCLOSURE Provided is a method for inducing T cells for a cell-based immunotherapy, comprising the steps of: () providing Rag 1 and/or Rag2 gene knockout human pluripotent stem cells bearing genes encoding a T cell receptor specific for a desired antigen, and (2) inducing T cells from the pluripotent stem cells of step (1). Further provided are a cell-based immunotherapy method that uses the T cells for the cell-based immunotherapy and an iPS cell bank for the cell-based immunotherapy. Figure for publication: None 66
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462026341P | 2014-07-18 | 2014-07-18 | |
US201462026332P | 2014-07-18 | 2014-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201900323SA true SG10201900323SA (en) | 2019-02-27 |
Family
ID=55078633
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201900323SA SG10201900323SA (en) | 2014-07-18 | 2015-07-17 | Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells |
SG11201701191WA SG11201701191WA (en) | 2014-07-18 | 2015-07-17 | Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701191WA SG11201701191WA (en) | 2014-07-18 | 2015-07-17 | Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170369850A1 (en) |
EP (1) | EP3170897B1 (en) |
JP (3) | JP6715482B2 (en) |
KR (1) | KR102654784B1 (en) |
CN (2) | CN107075484B (en) |
AU (1) | AU2015290554A1 (en) |
IL (1) | IL250132A0 (en) |
SG (2) | SG10201900323SA (en) |
WO (1) | WO2016010148A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106536718B (en) | 2014-05-21 | 2021-04-27 | 国立大学法人京都大学 | Method for producing pancreatic islet cells and therapeutic agent for pancreatic disease containing pancreatic islet cells |
WO2017159088A1 (en) * | 2016-03-16 | 2017-09-21 | 国立大学法人京都大学 | Method for preparing cultured cells or cultured tissue for transplantation |
JP2019080491A (en) * | 2016-03-16 | 2019-05-30 | 国立大学法人京都大学 | Method for inducing NY-ESO1 antigen-specific T cells for immune cell therapy |
HUE056387T2 (en) * | 2016-04-15 | 2022-02-28 | Univ Kyoto | Method for inducing antigen specific cd8 positive t cells |
WO2018007976A1 (en) * | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
JP7131775B2 (en) * | 2017-02-06 | 2022-09-06 | 国立研究開発法人国立がん研究センター | novel T-cell receptor |
KR102486691B1 (en) * | 2018-01-31 | 2023-01-11 | 고려대학교 산학협력단 | Human Induced Pluripotent Stem Cell Lines Reflecting Highly Polymorphic CYP Genotypes in Korean |
JPWO2020251046A1 (en) * | 2019-06-14 | 2020-12-17 | ||
GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
WO2021157685A1 (en) * | 2020-02-07 | 2021-08-12 | 学校法人順天堂 | Cytotoxic t cells derived from human t cell-derived ips cells |
GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
JP2023553419A (en) | 2020-12-03 | 2023-12-21 | センチュリー セラピューティクス,インコーポレイテッド | Genetically engineered cells and their uses |
WO2022145490A1 (en) * | 2021-01-04 | 2022-07-07 | サイアス株式会社 | Method for producing regenerated t cell via ips cell |
EP4320224A1 (en) | 2021-04-07 | 2024-02-14 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
CN117479952A (en) | 2021-04-07 | 2024-01-30 | 世纪治疗股份有限公司 | Combined artificial cell death/reporter polypeptides for chimeric antigen receptor cells and uses thereof |
AU2022253891A1 (en) | 2021-04-07 | 2023-08-24 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
IL307358A (en) | 2021-04-07 | 2023-11-01 | Century Therapeutics Inc | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
AU2022259170A1 (en) * | 2021-04-16 | 2023-10-12 | Thyas Co. Ltd. | Cell bank composed of ips cells for introducing t cell receptor gene |
CN113388612A (en) * | 2021-06-18 | 2021-09-14 | 重庆天科雅生物科技有限公司 | Primer designed for TCR with epitope point of IYVLVMLVL and application thereof |
AU2022423987A1 (en) | 2021-12-29 | 2024-07-11 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
IL314801A (en) | 2022-02-22 | 2024-10-01 | Juno Therapeutics Inc | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses |
WO2023215826A1 (en) | 2022-05-04 | 2023-11-09 | Century Therapeutics, Inc. | Cells engineered with an hla-e and hla-g transgene |
WO2023240212A2 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
WO2023240147A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof |
WO2024102838A1 (en) | 2022-11-09 | 2024-05-16 | Century Therapeutics, Inc. | Engineered interleukin-7 receptors and uses thereof |
WO2024103017A2 (en) | 2022-11-10 | 2024-05-16 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1891209A1 (en) * | 2005-06-06 | 2008-02-27 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for generating a t cell against an antigen of interest. |
CA2715305A1 (en) * | 2007-08-30 | 2009-03-05 | Genentech, Inc. | Methods and compositions for modulating t cells |
KR101811235B1 (en) * | 2009-06-05 | 2017-12-21 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | Reprogramming T cells and hematopoietic cells |
US9206394B2 (en) * | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
EP2853590B1 (en) * | 2012-05-22 | 2018-11-07 | The University of Tokyo | Method for producing antigen-specific t cells |
US20170128556A1 (en) * | 2013-12-26 | 2017-05-11 | Thyas Co. Ltd. | Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes |
-
2015
- 2015-07-17 SG SG10201900323SA patent/SG10201900323SA/en unknown
- 2015-07-17 JP JP2016534507A patent/JP6715482B2/en not_active Expired - Fee Related
- 2015-07-17 EP EP15821273.8A patent/EP3170897B1/en active Active
- 2015-07-17 KR KR1020177004390A patent/KR102654784B1/en active IP Right Grant
- 2015-07-17 WO PCT/JP2015/070608 patent/WO2016010148A1/en active Application Filing
- 2015-07-17 AU AU2015290554A patent/AU2015290554A1/en not_active Abandoned
- 2015-07-17 CN CN201580049887.6A patent/CN107075484B/en active Active
- 2015-07-17 SG SG11201701191WA patent/SG11201701191WA/en unknown
- 2015-07-17 US US15/326,977 patent/US20170369850A1/en active Pending
- 2015-07-17 CN CN202210036485.4A patent/CN114292817A/en active Pending
-
2017
- 2017-01-16 IL IL250132A patent/IL250132A0/en unknown
-
2020
- 2020-05-22 JP JP2020089304A patent/JP7072808B2/en active Active
-
2022
- 2022-04-25 JP JP2022071495A patent/JP7440027B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016010148A1 (en) | 2016-01-21 |
US20170369850A1 (en) | 2017-12-28 |
KR102654784B1 (en) | 2024-04-04 |
JP2022101655A (en) | 2022-07-06 |
CN114292817A (en) | 2022-04-08 |
SG11201701191WA (en) | 2017-03-30 |
EP3170897B1 (en) | 2020-05-13 |
CN107075484A (en) | 2017-08-18 |
AU2015290554A1 (en) | 2017-03-09 |
CN107075484B (en) | 2022-01-28 |
EP3170897A1 (en) | 2017-05-24 |
JP6715482B2 (en) | 2020-07-01 |
IL250132A0 (en) | 2017-03-30 |
KR20170042601A (en) | 2017-04-19 |
JP2020141695A (en) | 2020-09-10 |
EP3170897A4 (en) | 2018-03-07 |
JPWO2016010148A1 (en) | 2017-06-15 |
JP7440027B2 (en) | 2024-02-28 |
JP7072808B2 (en) | 2022-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201900323SA (en) | Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells | |
ZA202310779B (en) | Compositions and methods for enhanced gene expression | |
MX2021008143A (en) | Methods for harvesting mammalian cell cultures. | |
IL249828A0 (en) | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof | |
MY189778A (en) | Method for producing retinal pigment epithelial cells | |
SG10201810150UA (en) | Compositions and methods for enhanced gene expression in cone cells | |
PH12015501477A1 (en) | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells | |
IL248451A0 (en) | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy | |
MX2015015406A (en) | Arrays of discrete cell culture microenvironments, methods of making such arrays and uses thereof. | |
TW201612312A (en) | Meristematic plant cells and method of isolating them | |
EP4292600A3 (en) | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | |
SG10201903910RA (en) | Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same | |
EP3369809A4 (en) | Method for obtaining leydig cells by carrying out induced differentiation on human induced pluripotent stem cells, and use of leydig cells | |
CY1122993T1 (en) | PRODUCTION METHOD FOR PLRIPOTENTIAL STEM CELLS HAVING AN ANTIGEN-SPECIFIC T CELL RECEPTOR GENE | |
EP3170895A4 (en) | Production method for pluripotent stem cells having antigen-specific t cell receptor gene | |
EP3702444A4 (en) | Method for inducing differentiation of pluripotent stem cells into hepatocytes | |
MX2021001981A (en) | Methods of preparing a poloxamer for use in cell culture medium. | |
GB201608060D0 (en) | Method of culturing T cells | |
EP3162812A4 (en) | Mutant hemagglutinin complex protein, and method for culturing pluripotent stem cells using same | |
MX2019001946A (en) | Marker for neural stem cells. | |
IL281231A (en) | Methods of continuous cell culture | |
EP3194573A4 (en) | Mammalian pluripotent stem cells, methods for their production, and uses thereof | |
EP3587560A4 (en) | Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells | |
SG10201912931RA (en) | Pluripotent stem cell manufacturing system, method for inducing stem cells, floating culture method for stem cells, floating culture vessel for stem cells, method for producing induced pluripotent stem cells, and method for producing particular somatic cells from animal cells | |
EP3336178A4 (en) | Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for cell culturing |